A Phase 1b, Multi-center Study of Intravenous (IV) Gallium Nitrate in Patients with Cystic Fibrosis (CF) Who Are Colonized with Nontuberculous Mycobacteria (NTM) (The ABATE Study)

The purpose of this study is to assess the safety and tolerability of two 5-day infusion cycles of IV gallium in adult patients with CF who are infected with NTM.
Funding Source - FDA Office of Orphan Products Development (OOPD)

开始日期2021-06-17

申办/合作机构

Seattle Children's Hospital

[+1]

NCT03669614

/ Unknown status临床1/2期

A Phase 1/2a Randomized, Double-Blind, Two-Part, Dose-Ascending, Multicenter Study of the Safety and PK of AR-501 (Gallium Citrate), Administered Via Inhalation, in Healthy Adult and P. Aeruginosa Infected Cystic Fibrosis Subjects

This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmacokinetic (PK) profile of single and repeat administrations of inhaled AR-501 solution in healthy adults, and the safety, PK and efficacy of repeat administrations of inhaled AR-501 solution in P. aeruginosa infected CF subjects.

开始日期2018-12-07

申办/合作机构

Aridis Pharmaceuticals, Inc.

NCT02776891

/ Withdrawn临床2期IIT

A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Protein Expression in Diffuse Large B-Cell Lymphoma

This is a single center imaging study investigating the use of PET with 68Ga-citrate in patients with DLBCL or BCLU.

开始日期2016-06-13

申办/合作机构

The University of California, San Francisco

100 项与枸橼酸镓相关的临床结果

登录后查看更多信息

100 项与枸橼酸镓相关的转化医学

登录后查看更多信息

100 项与枸橼酸镓相关的专利（医药）

登录后查看更多信息

147

项与枸橼酸镓相关的文献（医药）

2023-09-04·Angewandte Chemie (International ed. in English)

Gallium Triggers Ferroptosis through a Synergistic Mechanism.

Article

作者: Zhang, Jun-Long ; Zhang, Hang ; Zhang, Ruijing ; Peng, Xin-Xin ; Gao, Song ; Yang, Zi-Shu ; Li, Ze-Hao ; Zhang, Jing

The gallium ion (Ga³⁺ ) has long been believed to disrupt ferric homeostasis in the body by competing with iron cofactors in metalloproteins, ultimately leading to cell death. This study revealed that through an indirect pathway, gallium can trigger ferroptosis, a type of non-apoptotic cell death regulated by iron. This is exemplified by the gallium complex of the salen ligand (Ga-1); we found that Ga-1 acts as an effective anion transporter that can affect the pH gradient and change membrane permeability, leading to mitochondrial dysfunction and the release of ferrous iron from the electron transfer chain (ETC). In addition, Ga-1 also targeted protein disulfide isomerases (PDIs) located in the endoplasmic reticulum (ER) membrane, preventing the repair of the antioxidant glutathione (GSH) system and thus enforcing ferroptosis. Finally, a combination treatment of Ga-1 and dietary polyunsaturated fatty acids (PUFAs), which enhances lipid peroxidation during ferroptosis, showed a synergistic therapeutic effect both in vitro and in vivo. This study provided us with a strategy to synergistically induce Ferroptosis in tumor cells, thereby enhancing the anti-neoplastic effect.

2022-05-04·New Zealand veterinary journal

Animal safety of a tall fescue endophyte (Epichloë sp.) in a perennial ryegrass (Lolium perenne) host

Article

作者: Mace, WJ ; Finch, SC ; Croy, RG ; van Koten, C ; Hume, DE ; Sutherland, BL

AIMS:

To assess animal health and production in sheep grazing perennial ryegrass (Lolium perenne) infected with a tall fescue endophyte (Epichloë sp.).

METHODS:

Three replicates of pure perennial ryegrass pastures infected with AR501 tall fescue endophyte (AR501 HE), AR1, AR37 or standard endophyte (STD) (all >85% infection) and a low endophyte control (AR501 LE) were grazed by 10 lambs for 7 weeks during late summer/early autumn, 2017. AR501 HE and AR501 LE were in the same tetraploid cultivar and the remaining treatments were in the same diploid cultivar. Lambs were weighed on Days 0, 19, 37 and 48 and assessed for ryegrass staggers on a 0-4 tremor scale nine times from Day 13. On Days 14 and 20, rectal temperatures and respiration rates were measured in lambs grazing AR501 HE, AR501 LE and STD under heat load. Pasture samples from each treatment were taken regularly (8 times) for analysis of known endophyte secondary metabolites.

RESULTS:

Peak mean ryegrass staggers scores for lambs grazing STD and AR37 treatments were 3.9 and 2.7, respectively, indicating environmental conditions were conducive to toxicity. Lambs grazing AR501 HE showed no ryegrass staggers at any date. The liveweight of STD lambs was up to 6.6 kg less than some or all other treatments on Days 19, 34 and 48, but there was no evidence of a difference between the liveweight of AR501 HE lambs and AR501 LE, AR37 or AR1 lambs on any date. Rectal temperatures and respiration rates of STD lambs were higher than AR501 HE lambs by 0.2°C and 26 breaths/minute, respectively. Apart from lower rectal temperature of AR501 HE lambs on Day 14, there was no evidence of differences between the AR501 HE and AR501 LE lambs. N-Formylloline was the only loline present in AR501 HE herbage (350-860 mg/kg). Peramine in AR501 HE herbage (42-77 mg/kg) was greater than that in STD and AR1 herbage on five and seven of the eight sampling dates, respectively.

CONCLUSION:

Lambs grazing AR501 HE showed no ryegrass staggers, exacerbated heat stress or suppressed liveweight gain compared with lambs grazing AR501 LE in a season when endophyte-induced toxicity was evident in STD and AR37 pastures. This suggests AR501 tall fescue endophyte does not produce toxic concentrations of secondary metabolites.

CLINICAL RELEVANCE:

This study suggests that there are no secondary metabolites produced by the tall fescue AR501 endophyte-perennial ryegrass association which affect animal health or production.

2021-03-31·Current radiopharmaceuticals

Physiological Animal Imaging with 68Ga-Citrate

Article

作者: Gültekin, Aziz ; Uğur, Ayşe

Background::

Objective::

In this study, by applying the 68Ge/68Ga generator product, a simple technique for the synthesis and quality control of 68Ga-citrate was introduced and was followed by preliminary animal studies.

Methods::

The synthesis of 68Ga-citrate was performed with a cationic method using the Scintomics automated synthesis system (Scintomics GmbH GRP module 4V). Since the standard procedure for quality control (QC) was not available, the definition of chemical and radiochemical purity of 68Ga-citrate was carried out according to the ICH Q2(R1) guideline. The standard QC tests were analysed with Scintomics 8100 radio-HPLC system equipped with a radioactivity detector. In this study, a New Zealand rabbit weighing 2520 g was used for PET/CT images.

Results::

Gallium-68 is an ideal research and hospital-based PET radioisotope. The uptake mechanism of Gallium citrate is a combination of specific and non-specific processes, for example, vasodilatation, increased vascular permeability, plasma 68Ga-citrate synthesis was performed by a cationic method without using organic solvents. The labelling efficiency was found to be >98%. The HPLC method used to assess the radiochemical purity of 68Ga -citrate was validated as rapid, accurate and reproducible enough to apply it to patients safely. The physiological distribution of 68Ga-citrate was investigated in a healthy rabbit. The blood pool, liver, spleen, kidneys and growth plates were the most common sites of 68Ga-citrate involvement. transferrin binding and lactoferrin and siderophores.

项与枸橼酸镓相关的新闻（医药）

2025-05-13

·Pharma CMC

远大医药RDC创新药计划今年申报上市，用于诊断前列腺癌！

5月12日晚，远大医药发布公告，其用于诊断前列腺癌的创新在研放射性核素偶联药物TLX591-CDx(Illuccix®,gallium Ga 68 PSMA-11)在中国进行的III期临床试验，近日已完成全部患者入组给药，并计划于今年内在中国递交新药上市申请。TLX591-CDx是一款全球创新、基于放射性核素-小分子偶联技术的靶向前列腺特异性膜抗原(「PSMA」)的诊断型放射性药物，适用于转移性前列腺癌及复发性前列腺癌的诊断。基于公开数据，TLX591-CDx中的靶向剂PSMA-11能以高亲和力的方式特异性结合在前列腺癌中高表达的PSMA上，具有可内化入细胞、生物学活性稳定、体内循环半衰期短以及对肿瘤实质的渗透性好且可被非靶向组织快速清除的五大特点。该项III期临床研究是一项单臂、开放标签的III期临床研究，拟在超过100例前列腺癌生化复发患者中使用TLX591-CDx并进行正电子发射断层成像/计算机断层扫描（PET/CT）或正电子发射断层成像/磁共振成像（PET/MRI）检测，以评估产品的诊断有效性，同时评估产品在中国人群中的安全性和耐受性。TLX591-CDx在全球范围内的注册上市工作正顺利推进。TLX591-CDx于2021年11月在澳大利亚获批上市，同年12月在美国获批上市；于2022年10月在加拿大获批上市；于2023年3月在美国批准扩展适应症，用于筛选可接受PSMA靶向放射性核素治疗的前列腺癌患者，并于2024年10月在澳大利亚、加拿大相继批准扩展该适应症；通过非集中审评程序，于2025年1月推荐在欧洲经济区国家上市，同年2月在英国获批上市，并通过互认程序，相继在丹麦、挪威、马耳他、卢森堡、荷兰、瑞典、法国、芬兰、爱尔兰、捷克获批上市；并于同年3月获得巴西批准上市。该产品已在2024年实现销售额7.83亿澳元（5.17亿美元）；2025年第一季度销售额为1.51亿美元，同比增长约35%。

临床3期上市批准

2025-05-12

·远大医药官微

远大医药创新RDC药物TLX591-CDx中国III期临床研究完成全部患者入组给药并计划今年内在中国递交新药上市申请

TLX591-CDx具有可内化入细胞、生物学活性稳定、体内循环半衰期短以及对肿瘤实质的渗透性好且可被非靶向组织快速清除的五大特点；TLX591-CDx在全球范围内的注册上市工作进展顺利，已在2024年实现销售额7.83亿澳元（5.17亿美元），2025年一季度销售额为1.51亿美元，同比增长约35%；此次III期临床试验全部患者入组给药将进一步加速推进TLX591-CDx在中国的上市进程，并计划今年内在中国递交新药上市申请，为公司实现前列腺癌“诊疗一体化”奠定坚实的基础。远大医药(0512.HK)用于诊断前列腺癌的创新在研放射性核素偶联药物(RDC) TLX591-CDx（Illuccix®, gallium Ga 68 PSMA-11)在中国进行的III期临床试验，近日已完成全部患者入组给药，并计划今年内在中国递交新药上市申请，这是公司在核药抗肿瘤诊疗领域的又一次重要研发进展。TLX591-CDx临床优势显著全球注册上市进展顺利关于本次临床研究该研究是一项单臂、开放标签的III期临床研究，拟在超过100例前列腺癌生化复发患者中使用TLX591-CDx并进行正电子发射断层成像/计算机断层扫描（PET/CT）或正电子发射断层成像/磁共振成像（PET/MRI）检测，以评估产品的诊断有效性，同时评估产品在中国人群中的安全性和耐受性。远大医药享有该产品在中国大陆、香港特别行政区、澳门特别行政区及台湾地区的独家开发及商业化权益。关于TLX591-CDx及其临床研究TLX591-CDx是一款全球创新、基于放射性核素-小分子偶联技术的靶向前列腺特异性膜抗原(PSMA)的诊断型放射性药物，适用于转移性前列腺癌及复发性前列腺癌的诊断。基于公开数据，TLX591-CDx中的靶向剂PSMA-11能以高亲和力的方式特异性结合在前列腺癌中高表达的PSMA上，具有可内化入细胞、生物学活性稳定、体内循环半衰期短以及对肿瘤实质的渗透性好且可被非靶向组织快速清除的五大特点。该产品在全球范围内的注册上市工作正顺利推进。TLX591-CDx于2021年11月在澳大利亚获批上市，同年12月在美国获批上市；于2022年10月在加拿大获批上市；于2023年3月在美国批准扩展适应症，用于筛选可接受PSMA靶向放射性核素治疗的前列腺癌患者，并于2024年10月在澳大利亚、加拿大相继批准扩展该适应症，通过非集中审评程序，于2025年1月推荐在欧洲经济区国家上市，同年2月在英国获批上市，并通过互认程序，相继在丹麦、挪威、马耳他、卢森堡、荷兰、瑞典、法国、芬兰、爱尔兰、捷克获批上市；并于同年3月获得巴西批准上市。该产品已在2024年实现销售额7.83亿澳元（5.17亿美元）；2025年一季度销售额为1.51亿美元，同比增长35%。该产品海外临床研究方面，TLX591-CDx于2022年2月在日本完成一项纳入10例受试者的I期试验，研究结果显示该产品安全与耐受性良好，在所有受试者中均未观察到严重不良事件，全身和器官特异性辐射剂量测定以及药代动力学数据表明，日本人种和西方人种之间没有显著差异。TLX591-CDx已于2023年8月在中国完成III期临床试验首例患者给药。此次III期临床试验全部患者入组给药有望进一步加速推进该产品在中国的上市进程，为公司实现前列腺癌“诊疗一体化”奠定坚实的基础。近期，用于治疗前列腺癌的RDC产品TLX591国际多中心III期临床研究在中国顺利获得受理，未来，随着该临床研究积极推进，两款产品组合蓄势待发，有望为中国前列腺疾病患者带来更为精准、高效的诊疗方案。持续推进创新产品研发夯实全球核药领军地位核药抗肿瘤诊疗板块是远大医药的重点布局的领域之一。围绕肿瘤诊疗一体化的治疗理念，公司核药抗肿瘤诊疗板块目前已储备12款创新产品，涵盖68Ga、177Lu、131I、90Y、89Zr在内的5种放射性核素，覆盖了肝癌、前列腺癌、脑癌等在内的7个癌种；在产品种类方面，涵盖诊断和治疗两类核素药物，为患者提供多适应症治疗选择、多手段且诊疗一体化的全球领先的抗肿瘤方案。目前，远大医药在核药抗肿瘤诊疗板块已有4款RDC创新药获批开展注册性临床研究，其中3款已进入III期临床阶段：用于诊断前列腺癌的产品TLX591-CDx预计将于今年二季度完成全部患者入组；诊断肾透明细胞癌产品TLX250-CDx已于2024年11月完成首例患者入组给药；以及治疗胃肠胰腺神经内分泌瘤的产品ITM-11已于2025年3月完成国际多中心COMPOSE试验的中国首例患者入组给药。截至目前，远大医药是进入中国III期临床研究中诊断和治疗类RDC创新药总计储备最多的企业，也是全球范围内在核药抗肿瘤领域拥有最丰富产品管线和诊疗一体化布局的创新药企之一。关于远大医药核药抗肿瘤诊疗平台核药抗肿瘤诊疗平台是公司在抗肿瘤领域重点打造的高端技术平台，目前公司已实现了研发、生产、销售、监管资质等多个环节的全方位布局，建立了完整的产业链。远大医药联合Sirtex Medical Pty Limited并与Telix Pharmaceutical Limited (ASX: TLX; NASDAQ: TLX)和ITM Isotope Technologies Munich SE合作，搭建了具有国际化一流水平的肿瘤介入研发平台和RDC药物研发平台，已拥有约800名员工，是公司全球化程度最高的板块之一。同时，公司与山东大学联合成立了远大医药-山东大学放射药物研究院，并以该研究院为起点，逐步完成了核药早期研发平台的建设，进行RDC药物的自主研发，目前早期研发阶段的产品储备已达12款。公司正在有序推进成都甲级资质核素生产平台的建设，已于今年3月正式完成辐射安全许可证现场检查，即将投入运营。该基地定位于全球创新核药产业化高地，聚焦同位素工艺开发与制备、核药偶联技术、自动化标记技术等核心领域，覆盖核药早研、工艺开发、质控、非临床研究、智能生产与精准配送一站式全生命周期管理，树立世界一流研发生产质量与运营体系。此外，该基地通过全流程智能监控与闭环管理，致力于建设全球首个零辐射智能核药工厂，是目前国际范围内核素种类最全、自动化程度最高的智能工厂。同时，该基地也将与远大医药美国波士顿研发中心、远大医药-山东大学放射药物研究院等共同构建成为其全球核药研发中心网络，并依托科技创新、全球人才与智能制造，全面夯实公司在核药领域的领先地位。随着成都核药基地投入使用，公司全球创新核药管线的落地将进入新的阶段，不仅有助于公司培育更多高价值的重磅核药品种，更将进一步稳固公司在核药产业全球化发展的前进步伐。远大医药正在有序推进甲级资质核素生产平台的建设。未来，公司将持续加强核药抗肿瘤诊疗板块的研发和建设，丰富和完善产品管线及产业布局，形成以易甘泰®钇[90Y]微球注射液为核心的核药抗肿瘤诊疗产品集群，持续夯实公司在全球核药抗肿瘤诊疗领域领军企业地位。远大医药集团有限公司董事会表示：“本集团一直高度重视创新产品和先进技术的研发，未来将持续加大对全球创新产品和先进技术的投入，丰富和完善产品管线及产业布局，坚持‘全球化运营布局，双循环经营发展’策略，充分发挥本集团的产业优势和研发实力，快速将科技创新产品落地上市，为全球患者提供更先进更多样的治疗方案。”▲再传捷报！远大医药全球创新RDC产品TLX591加入国际多中心III期临床试验的申请已获国家药监局受理▲ 全球首个！远大医药全球创新产品STC3141中国II期临床研究成功达到临床终点▲远大医药丙酸氟替卡松鼻喷雾剂获批上市↑↓ 上下滑动了解更多➤关于远大医药远大医药（0512.HK）是一家科技创新型国际化医药企业，核心业务横跨制药科技、核药抗肿瘤诊疗及心脑血管精准介入诊疗科技、生物科技三大领域。集团以医药及生物工业为基础，以患者需求为核心，以科技创新为源动力，针对尚未满足的临床需求，加大对全球创新产品和先进技术的投入，丰富和完善产品管线，巩固和强化产业链布局，充分发挥本集团的产业优势和研发实力，为全球患者提供更先进更多样的治疗方案。经过近年的不懈努力，本集团发展基础更加稳健，经营规模更加巩固，业务结构逐步优化，经营方式持续提升，转型升级步伐加快，创新布局多点开花。本集团盈利能力持续增强，助力研发创新；良好的并购与整合能力，继续巩固发展规模；原料制剂一体化，完善产业链结构；业务与实体多元化，有效加强综合优势。“稳增长、强创新、谋布局”，本集团将继续秉承“综合优势、创新引领和全球拓展”的发展理念，采用“自主研发和全球拓展双轮驱动，全球化运营布局和双循环经营发展”策略，形成国内国外双循环联动发展并相互促进的新格局，致力于成为一家受医生和患者尊重并还原于社会的科技创新型国际化医药企业。 ➤前瞻性声明本新闻稿中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用“预期”、“相信”、“预测”、“期望”、“打算”及其他类似词语进行表述时，凡与本集团有关的，均属于前瞻性表述。本集团并无义务不断地更新这些预测性陈述。这些前瞻性表述是基于本集团管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险不确性及其他因素的影响，有些是超出本集团的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本集团、本集团董事及雇员代理概不承担(1)更正或更新本网站所载前瞻性表述的任何义务;及(2)若因任何前瞻性表述不能实现或变成不正确而引致的任何责任。

临床3期上市批准

2025-03-10

·PRNewswire

Isotopia Announces Official Commercial Launch of Isoprotrace® in Germany in Partnership with DSD Pharma

PETAH TIKVA, Israel, March 10, 2025 /PRNewswire/ -- Isotopia, a leading developer of innovative radio-pharmaceuticals, has officially launched Isoprotrace® in Germany. DSD Pharma, a trusted pharmaceutical distributor in Germany, will serve as the exclusive partner for the distribution of Isoprotrace® throughout the country, ensuring efficient, consistent delivery to hospitals, clinics, and diagnostic centres across Germany. This partnership also extends to the distribution of our Lutetium (177 Lu) Chloride n.c.a., further enhancing our portfolio of advanced cancer imaging and treatment solutions. Isoprotrace® is a cutting-edge radiopharmaceutical product used for prostate cancer imaging. This multi-dose kit allows for the rapid and efficient preparation of Gallium (68Ga) Gozetotide solution for intravenous (I.V.) injection. After radiolabelling with gallium (68Ga) chloride solution, Isoprotrace® is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer in the following clinical settings: Primary staging of patients with high–risk prostate cancer prior to primary curative therapy. Suspected prostate cancer recurrence based on elevated serum prostate-specific antigen (PSA) levels, after primary curative therapy. Prostate cancer remains one of the most common cancers among men in Germany, with over 70,000 new cases diagnosed each year. Accurate imaging plays a crucial role in precise diagnosis and effective treatment planning. "We are thrilled to be working with DSD Pharma to bring Isoprotrace® to the German market," said Tzachi Levy, GM of Isotopia's aseptic plant "Germany is a key market for Isoprotrace®, and we are confident that this collaboration will ensure the successful introduction and accessibility of this innovative product to healthcare providers across the country." Dr. Susanne Dorudi, Managing Director at DSD Pharma, added, "We are proud to partner with Isotopia to introduce Isoprotrace® to Germany. This collaboration allows us to offer German healthcare professionals a groundbreaking imaging solution. We are excited about the potential impact of this product and look forward to its success in the German market." Isoprotrace® has already been approved in the Netherlands and is expected to be available soon in over 10 EU countries. With a robust and reliable supply chain and a proven compliance record, Isotopia is committed to expanding patient access to this innovative product, while enhancing diagnostic accuracy and improving treatment outcomes for prostate cancer. About Isotopia Isotopia is a leading innovator in the development of radiopharmaceuticals for molecular imaging and therapy. With a focus on providing top-quality, advanced solutions, Isotopia is committed to improving patient care through precision medicine. About DSD Pharma DSD Pharma is a well-established pharmaceutical distribution company operating in Austria, Germany, and Switzerland, specializing in the distribution of cutting-edge healthcare solutions. With a strong network and profound expertise in the pharmaceutical industry, DSD Pharma partners with leading global companies to bring innovative products to the market. Contact: [email protected] Logo - SOURCE Isotopia WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与枸橼酸镓相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
呼吸道感染	临床2期	美国	-	2021-05-06
囊性纤维化	临床2期	美国	Aridis Pharmaceuticals, Inc.	2018-12-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03669614 (Corporate Publications) 人工标引	临床1/2期	囊性纤维化	96	AR-501 (healthy adult volunteers)	製醖餘蓋顧餘襯鹹構膚(鬱淵齋鏇窪齋艱淵廠鏇) = No serious adverse events (SAEs), no Grade 3 or Grade 4 adverse events (AEs) reported All AEs were Grade 1 or Grade 2 in severity that resolved Most common AEs were respiratory and were balanced between AR-501 and placebo recipients 衊壓壓繭獵積繭艱選繭 (範壓願衊積鑰夢顧遞鹹 )	积极	2020-06-22
NCT03669614 (Corporate Publications) 人工标引	临床1/2期	囊性纤维化	96	AR-501 (cystic fibrosis patients)		积极	2020-06-22
ASCO2007	临床2期	非霍奇金淋巴瘤	22	Gallium nitrate, rituximab, and dexamethasone	鹹壓遞範壓範鹽構製遞(餘築糧鹽淵鏇餘網範鹽) = 範淵簾蓋衊膚襯願衊願願簾齋築獵顧積鹽鏇鹽 (鹹鑰膚簾築選艱繭選蓋 ) 更多	-	2007-06-20